Skip to main content
UniHealth

Doctor search

Milana V Dolezal, MD

Hematology/Oncology · Stanford

NPI 1174777643

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
9
1 carrier
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dolezal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence A74043 · Current

Licensed to practise in California · since 2001 · expires 2026-11-30 · Jefferson Medical College of Thomas Jefferson University.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

4 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
  • Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp

Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Alta Bates Summit Medical Center - Alta Bates Camp
Clostridium Difficile (C.Diff)Infections0.298BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.18 (0.16 to 2.2) · 730 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.87 (0.51 to 1.23)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths188.12 (132.31 to 243.94) · 50 casesNo differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths6.8 · 50 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.8 · 41 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.4 · 189 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12.6 · 184 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 103 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 1,585 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.18 (0 to 0.4) · 3,929 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.31 (0.11 to 0.51) · 3,954 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.15 (0.95 to 5.36) · 754 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.62 (0 to 3.33) · 325 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.99 (0.39 to 3.59) · 717 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.85 (2.27 to 19.44) · 326 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.79 (1.08 to 8.49) · 302 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.68 (0.19 to 3.18) · 184 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.17 (0 to 0.88) · 3,240 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.4 · 161 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.207No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.48No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.785No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.4 · 243 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-58.2 · 194 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-12.3 · 177 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 209 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.4 (3.8 to 7.5) · 215 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.2 (9.4 to 15.5) · 215 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.8 · 150 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.2 · 81 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.4 (10 to 18.1) · 315 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.6 to 1.2) · 137 casesNo differentJan 2024 – Dec 2024

What patients said (449 patients answered, 15% of those asked)

Patient survey stars by topic at Alta Bates Summit Medical Center - Alta Bates Camp
Cleanliness2
Nurse communication2
Doctor communication2
Communication about medicines2
Discharge information2
Overall hospital rating2
Quietness2
Recommend hospital3
Share of patients giving the best answer at Alta Bates Summit Medical Center - Alta Bates Camp
Room was "always" clean62%
Nurses "always" communicated well72%
Doctors "always" communicated well75%
Staff "always" explained53%
Yes, staff "did" give patients this information82%
Yes, staff "did" give patients information about help after discharge82%
Doctors "always" explained things so they could understand68%
Doctors "always" listened carefully73%
Doctors "always" treated them with courtesy and respect83%
Patients who gave a rating of "9" or "10" (high)58%
Staff "always" explained new medications67%
Nurses "always" explained things so they could understand67%
Nurses "always" listened carefully66%
Nurses "always" treated them with courtesy and respect81%
"Always" quiet at night49%
"YES", patients would definitely recommend the hospital67%
Staff "always" explained possible side effects38%
Yes, staff "did" give patients information about possible symptoms83%
See every measure and the patient survey for Eden Medical Center

Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Eden Medical Center
Clostridium Difficile (C.Diff)Infections0.122BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.88 (0 to 1.89) · 819 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.81 (0.46 to 1.16)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths137.41 (92.94 to 181.88) · 70 casesNo differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths8.4 · 78 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.7 · 38 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11.1 · 207 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths17.6 · 359 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.5 · 355 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.4 · 1,714 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.17 (0 to 0.39) · 4,697 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.3 (0.1 to 0.5) · 4,676 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.69 (0.53 to 4.85) · 860 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.56 (0 to 3.24) · 251 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.75 (1.17 to 4.32) · 818 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.76 (0 to 15.78) · 261 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths6.09 (2.08 to 10.1) · 242 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.64 (0.16 to 3.12) · 233 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.85) · 4,132 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.9 · 60 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.431No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.292No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.307No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.61No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22.1 · 258 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits22.6 · 225 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits2.4 · 367 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.9 · 390 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 58 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 88 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.9 (9.6 to 17.4) · 68 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.6 to 1.1) · 205 casesNo differentJan 2024 – Dec 2024

What patients said (431 patients answered, 17% of those asked)

Patient survey stars by topic at Eden Medical Center
Cleanliness3
Nurse communication2
Doctor communication2
Communication about medicines2
Discharge information3
Overall hospital rating3
Quietness3
Recommend hospital4
Share of patients giving the best answer at Eden Medical Center
Room was "always" clean71%
Nurses "always" communicated well75%
Doctors "always" communicated well75%
Staff "always" explained57%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand70%
Doctors "always" listened carefully73%
Doctors "always" treated them with courtesy and respect82%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications70%
Nurses "always" explained things so they could understand69%
Nurses "always" listened carefully71%
Nurses "always" treated them with courtesy and respect83%
"Always" quiet at night58%
"YES", patients would definitely recommend the hospital75%
Staff "always" explained possible side effects43%
Yes, staff "did" give patients information about possible symptoms87%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$98,744

Medicare paid this office $98,744 for 364 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)207$55,114$132
Return visit (30+ min)219$27,079$82
New patient visit (60+ min)100$15,908$159

Who their Medicare patients are

364 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 15% · Women 68% · Also on Medicaid 14% · Health risk score 1.52. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 69% · Cancer 49% · Chronic kidney disease 29% · Diabetes 23% · Depression 21% · Coronary heart disease 20% · Atrial fibrillation 20% · Heart failure 14% · COPD 14% · Stroke 7% · Dementia 5%.

The office billed $314,488, Medicare allowed $135,457 and paid $98,744; for 926 services of 8 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024364926761.52$314,488$98,744
2023264742751.52$252,602$82,036
2022181759751.40$195,445$72,968
202129139,646761.68$2,828,555$836,512
202029924,746751.84$1,448,704$404,912
201933345,167751.95$2,445,592$649,722
201828954,152741.81$1,966,371$607,362
20173511,331742.34$452,800$98,666
20163081,143722.17$390,658$87,804
20153361,171732.22$417,353$94,256
20142741,053732.27$384,144$81,094
20132571,044722.46$368,836$80,186

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Long return visit (40+ min)125$40,844$126
Return visit (30+ min)153$21,143$76
New patient visit (60+ min)130$18,840$145

2022: 3 services

Original Medicare services billed in 2022
Return visit (30+ min)129$26,760$87
New patient visit (60+ min)151$24,173$160
Long return visit (40+ min)59$13,607$126

2021: 27 services

Original Medicare services billed in 2021
Injection, denosumab, 1 mg27$99,223None
Return visit (30+ min)197$52,218$117
Long return visit (40+ min)85$35,915$168
Administration of chemotherapy into vein, 1 hour or less49$27,436$152
Injection, pegfilgrastim, 6 mg24$16,194None
New patient visit (60+ min)31$6,241$201
Administration of additional new drug or substance into vein, 1 hour or less23$5,770$74
Short return visit (20+ min)65$5,558$77
Transitional care management services for problem of high complexity13$5,343$267
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less36$4,232$32
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$4,225$92
Injection of additional new drug or substance into vein49$3,842$17
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count116$3,434$8
Injection of drug or substance under skin or into muscle61$2,919$13
Administration of chemotherapy into vein, each additional hour18$2,273$32
Injection of drug or substance into vein23$2,099$42
Aspiration of bone marrow sample for diagnosis11$2,048$171
Biopsy of bone marrow11$988$82
Application of on-body injector for under skin injection23$964$20
Injection, palonosetron hcl, 25 mcg27$762None
Insertion of needle into vein for collection of blood sample68$462$3
Injection, dexamethasone sodium phosphate, 1 mg33$151None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg12$98None
Injection, diphenhydramine hcl, up to 50 mg13$47None
Unclassified drugs19$39None
Injection, heparin sodium, (heparin lock flush), per 10 units13$26None
Injection, midazolam hydrochloride, per 1 mg11$5None

2020: 23 services

Original Medicare services billed in 2020
Injection, denosumab, 1 mg22$53,523None
Return visit (30+ min)169$35,244$96
Long return visit (40+ min)56$13,269$134
Administration of chemotherapy into vein, 1 hour or less44$12,286$146
Injection, pegfilgrastim, 6 mg13$8,572None
New patient visit (60+ min)26$4,842$186
Extended patient service without direct patient contact, first hour24$4,698$100
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$3,952$94
Telephone medical discussion with physician, 21-30 minutes25$3,329$101
Short return visit (20+ min)37$2,784$66
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less29$2,064$31
Administration of additional new drug or substance into vein, 1 hour or less15$1,905$71
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count101$1,900$8
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$1,875$65
Injection of drug or substance under skin or into muscle50$1,761$13
Injection of additional new drug or substance into vein36$1,623$17
Injection of drug or substance into vein22$1,497$40
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less11$976$70
Injection, palonosetron hcl, 25 mcg24$730None
Application of on-body injector for under skin injection12$478$20
Insertion of needle into vein for collection of blood sample46$200$3
Injection, heparin sodium, (heparin lock flush), per 10 units21$134None
Injection, dexamethasone sodium phosphate, 1 mg29$58None

2019: 33 services

Original Medicare services billed in 2019
Return visit (30+ min)168$43,036$98
Injection, denosumab, 1 mg21$36,539None
Administration of chemotherapy into vein, 1 hour or less50$23,821$146
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes59$22,772$94
Injection, pegfilgrastim, 6 mg12$21,351None
New patient visit (60+ min)47$9,031$192
Long return visit (40+ min)41$8,191$137
Other chemotherapy procedure11$6,580$165
Injection, palonosetron hcl, 25 mcg30$6,209None
Initial hospital care with moderate level of medical decision making at least 75 minutes25$4,741$182
Short return visit (20+ min)60$4,682$65
Extended patient service without direct patient contact, first hour36$4,247$97
Administration of additional new drug or substance into vein, 1 hour or less24$4,240$71
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less36$3,833$32
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count114$3,409$8
Injection of additional new drug or substance into vein51$3,334$17
Administration of chemotherapy into vein, each additional hour21$2,566$31
Injection of drug or substance under skin or into muscle43$2,351$16
Infusion into a vein for hydration, 31-60 minutes18$2,305$37
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes14$2,179$62
Aspiration of bone marrow sample for diagnosis12$2,002$167
Injection, levoleucovorin, not otherwise specified, 0.5 mg11$1,361None
Injection of drug or substance into vein22$1,337$39
Biopsy of bone marrow12$935$78
Application of on-body injector for under skin injection12$588$20
Injection, heparin sodium, (heparin lock flush), per 10 units18$417None
Insertion of needle into vein for collection of blood sample57$382$3
Injection, dexamethasone sodium phosphate, 1 mg36$115None
Infusion, normal saline solution , 1000 cc18$103None
Injection, fluorouracil, 500 mg12$92None
Unclassified drugs18$45None
Injection, diphenhydramine hcl, up to 50 mg16$22None
Injection, midazolam hydrochloride, per 1 mg12$6None

2018: 21 services

Original Medicare services billed in 2018
Return visit (30+ min)114$24,119$100
Administration of chemotherapy into vein, 1 hour or less34$17,411$146
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes58$14,941$65
Injection, denosumab, 1 mg16$13,799None
Long return visit (40+ min)83$11,459$125
Injection, palonosetron hcl, 25 mcg12$6,632None
Short return visit (20+ min)71$6,139$67
Initial hospital care with moderate level of medical decision making at least 75 minutes22$4,501$180
Extended patient service without direct patient contact, first hour47$4,486$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$4,261$93
New patient visit (60+ min)20$3,639$182
Administration of additional new drug or substance into vein, 1 hour or less12$3,066$70
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count92$2,688$9
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less17$2,326$31
Injection of drug or substance under skin or into muscle34$2,166$20
Injection of additional new drug or substance into vein31$2,137$18
Injection of drug or substance into vein15$992$47
Short return visit14$839$42
Insertion of needle into vein for collection of blood sample35$268$3
Injection, dexamethasone sodium phosphate, 1 mg15$49None
Unclassified drugs12$31None

2017: 7 services

Original Medicare services billed in 2017
Return visit (30+ min)238$44,849$64
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes71$15,380$90
Long return visit (40+ min)110$12,629$88
Initial hospital care with moderate level of medical decision making at least 75 minutes56$10,624$177
Short return visit (20+ min)53$7,627$44
New patient visit (60+ min)38$5,294$139
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$1,202$63

2016: 7 services

Original Medicare services billed in 2016
Return visit (30+ min)177$31,929$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes89$23,040$89
Initial hospital care with moderate level of medical decision making at least 75 minutes50$8,563$171
New patient visit (60+ min)51$7,248$142
Long return visit (40+ min)46$6,495$93
Short return visit (20+ min)42$5,004$44
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes46$3,906$62

2015: 7 services

Original Medicare services billed in 2015
Return visit (30+ min)175$27,865$64
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes92$22,663$89
Long return visit (40+ min)129$17,840$91
Initial hospital care with moderate level of medical decision making at least 75 minutes67$11,781$171
New patient visit (60+ min)39$5,335$137
Short return visit (20+ min)58$4,839$41
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes28$2,663$62

2014: 6 services

Original Medicare services billed in 2014
Return visit (30+ min)169$28,878$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes70$21,965$89
Long return visit (40+ min)80$12,141$91
Initial hospital care with moderate level of medical decision making at least 75 minutes31$5,910$174
New patient visit (60+ min)41$5,741$140
Short return visit (20+ min)58$5,399$43

2013: 6 services

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes72$25,559$87
Return visit (30+ min)149$24,891$61
Long return visit (40+ min)63$12,705$89
Initial hospital care with moderate level of medical decision making at least 75 minutes39$7,220$168
Short return visit (20+ min)43$4,315$41
New patient visit (60+ min)26$3,605$139

Medicaid work

$31 in 2021

Medicaid paid $31 for 14 billed services this clinician did in 2021, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2021
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count14$31
Medicaid work by year
202114112$31
202043213$134
See the largest Medicaid services in earlier years

2020

Largest Medicaid services in 2020
Return visit (30+ min)12$75
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count31$59

Drugs they prescribed that Part D paid

$1,060,622

Pharmacies billed $1,060,622 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

488 generic and 141 brand-name prescriptions · $1,060,622 in drug cost · 30 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Verzenio14$212,916$15,208
Brukinsa14$202,938$14,496
Ibrance11$155,483$14,135
Eliquis51$40,332$791
Enoxaparin19$5,994$315
See all 18 drugs
Every Part D drug this clinician prescribed
Verzenio14$212,916$15,208
Brukinsa14$202,938$14,496
Ibrance11$155,483$14,135
Eliquis51$40,332$791
Enoxaparin19$5,994$315
Anastrozole100$2,075$21
Exemestane13$1,510$116
Tamoxifen Citrate55$1,199$22
Bicalutamide16$554$35
Prochlorperazine Maleate26$291$11
Mirtazapine13$267$21
Allopurinol17$246$14
Venlafaxine Hcl Er13$193$15
Loperamide21$170$8
Acyclovir13$142$11
Prednisone25$119$5
Ondansetron27$117$4
Sulfamethoxazole-Trimethoprim27$53$2

Year by year

Part D prescribing by year
2024629145None22%$1,060,622
2023459112NoneNone$786,333
2022414123None25%$485,182
20211,3441511% (16)38%$3,097,803
20201,337154None30%$2,410,391
20191,1191621% (14)32%$1,878,020
20189422032% (23)26%$1,542,663
20171,2121726% (70)15%$1,056,496
20161,0991568% (89)None$741,509
20159351587% (64)None$479,674
20148451428% (70)None$463,238
20131,0501329% (98)None$462,041

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 14 drugs

Part D drugs prescribed in 2023
Verzenio16$265,328$16,583
Brukinsa12$185,677$15,473
Eliquis45$42,662$948
Exemestane15$4,536$302
Anastrozole55$1,312$24
Tamoxifen Citrate38$750$20
Hydroxyurea19$732$39
Ibandronate16$677$42
Ondansetron34$362$11
Acyclovir23$350$15
Prochlorperazine Maleate25$271$11
Dexamethasone16$264$16
Sulfamethoxazole-Trimethoprim21$257$12
Prednisone11$59$5

2022: 12 drugs

Part D drugs prescribed in 2022
Phesgo11$101,149$9,195
Eliquis25$18,651$746
Exemestane22$6,682$304
Anastrozole62$1,695$27
Ibandronate19$1,072$56
Tamoxifen Citrate18$615$34
Letrozole14$544$39
Hydroxyurea15$529$35
Ondansetron24$281$12
Prochlorperazine Maleate19$250$13
Acyclovir12$161$13
Alendronate12$18$2

2021: 40 drugs

Part D drugs prescribed in 2021
Neulasta Onpro63$432,583$6,866
Revlimid27$425,051$15,743
Nerlynx13$240,671$18,513
Aranesp39$174,340$4,470
Ibrance12$164,441$13,703
Keytruda15$160,109$10,674
Verzenio13$149,476$11,498
Xgeva45$118,591$2,635
Abraxane15$105,711$7,047
Perjeta15$104,486$6,966
Herceptin17$82,044$4,826
Imatinib Mesylate13$60,106$4,624
Nplate16$36,160$2,260
Akynzeo25$24,496$980
Creon18$18,577$1,032
Zarxio20$17,609$880
Eliquis28$17,404$622
Prolia12$17,190$1,432
Exemestane44$10,321$235
Levoleucovorin15$9,797$653
Palonosetron50$9,510$190
Oxaliplatin18$5,131$285
Anastrozole122$4,404$36
Gemcitabine18$3,762$209
Tamoxifen Citrate65$3,027$47
Paclitaxel20$2,632$132
Fosaprepitant Dimeglumine14$2,566$183
Ibandronate38$2,446$64
Hydroxyurea41$1,961$48
Letrozole43$1,932$45
Raloxifene15$1,132$75
Carboplatin15$791$53
Acyclovir31$512$17
Ondansetron21$381$18
Dexamethasone27$359$13
Prochlorperazine Maleate24$349$15
Mirtazapine14$308$22
Alendronate25$177$7
Sulfamethoxazole-Trimethoprim27$121$4
Gabapentin13$102$8

2020: 33 drugs

Part D drugs prescribed in 2020
Neulasta Onpro58$423,715$7,305
Kadcyla13$129,925$9,994
Nplate32$121,497$3,797
Verzenio13$77,645$5,973
Aranesp16$70,641$4,415
Erbitux12$66,576$5,548
Xgeva21$50,536$2,406
Imatinib Mesylate12$44,768$3,731
Akynzeo51$37,475$735
Zarxio20$24,731$1,237
Levoleucovorin33$19,471$590
Cyclophosphamide17$15,492$911
Exemestane25$10,112$404
Oxaliplatin40$8,959$224
Eliquis14$6,797$485
Anastrozole127$4,308$34
Fosaprepitant Dimeglumine18$4,130$229
Raloxifene26$3,018$116
Tamoxifen Citrate45$2,977$66
Palonosetron27$2,350$87
Irinotecan24$2,263$94
Hydroxyurea41$2,255$55
Ibandronate34$2,082$61
Letrozole40$1,505$38
Dexamethasone47$659$14
Acyclovir45$648$14
Prochlorperazine Maleate39$558$14
Ondansetron21$368$18
Alendronate22$254$12
Pantoprazole18$247$14
Prednisone26$138$5
Gabapentin14$126$9
Sulfamethoxazole-Trimethoprim30$104$3

2019: 31 drugs

Part D drugs prescribed in 2019
Neulasta36$229,692$6,380
Verzenio23$203,714$8,857
Promacta11$194,133$17,648
Ibrance15$181,498$12,100
Aranesp47$134,137$2,854
Avastin23$104,272$4,534
Xgeva26$61,170$2,353
Creon13$19,582$1,506
Exemestane31$13,237$427
Akynzeo18$12,945$719
Docetaxel11$12,093$1,099
Levoleucovorin16$7,160$447
Xarelto12$7,103$592
Eliquis16$7,050$441
Oxaliplatin13$4,225$325
Anastrozole148$3,866$26
Raloxifene18$3,404$189
Tamoxifen Citrate56$3,188$57
Ibandronate25$2,232$89
Hydroxyurea48$2,134$44
Letrozole61$1,563$26
Leucovorin11$1,392$127
Dexamethasone37$625$17
Prochlorperazine Maleate30$558$19
Ondansetron17$288$17
Acyclovir16$254$16
Pantoprazole18$175$10
Prednisone27$164$6
Alendronate17$94$6
Sulfamethoxazole-Trimethoprim15$86$6
Lorazepam12$57$5

2018: 19 drugs

Part D drugs prescribed in 2018
Ibrance26$309,851$11,917
Tagrisso13$197,716$15,209
Neulasta12$95,348$7,946
Aranesp29$60,828$2,098
Xgeva26$59,762$2,299
Faslodex20$41,599$2,080
Exemestane24$13,140$547
Raloxifene26$5,288$203
Anastrozole188$4,450$24
Tamoxifen Citrate107$4,142$39
Ibandronate26$2,959$114
Hydroxyurea39$1,573$40
Letrozole36$762$21
Dexamethasone43$313$7
Pantoprazole12$114$10
Alendronate14$110$8
Prednisone17$102$6
Prochlorperazine Maleate14$83$6
Lorazepam23$80$3

2017: 28 drugs

Part D drugs prescribed in 2017
Xtandi20$224,081$11,204
Tagrisso12$173,496$14,458
Ibrance13$141,041$10,849
Zytiga14$136,397$9,743
Exemestane55$26,336$479
Enoxaparin24$14,990$625
Creon15$12,526$835
Ibandronate33$3,682$112
Tamoxifen Citrate108$3,364$31
Anastrozole183$3,362$18
Ondansetron54$916$17
Gabapentin45$882$20
Bicalutamide23$564$25
Hydrocodone-Acetaminophen24$539$22
Morphine Sulfate Er14$476$34
Prochlorperazine Maleate57$353$6
Oxycodone12$308$26
Venlafaxine24$278$12
Pantoprazole33$272$8
Dexamethasone22$271$12
Nystatin16$258$16
Lorazepam55$205$4
Prednisone27$182$7
Letrozole15$156$10
Potassium Chloride11$112$10
Amlodipine Besylate26$105$4
Alendronate11$65$6
Levofloxacin13$55$4

2016: 24 drugs

Part D drugs prescribed in 2016
Ibrance21$219,847$10,469
Xtandi13$119,852$9,219
Tarceva16$116,798$7,300
Exemestane66$19,146$290
Enoxaparin15$8,332$555
Xarelto23$8,101$352
Anastrozole180$3,056$17
Tamoxifen Citrate95$2,279$24
Ibandronate15$2,079$139
Morphine Sulfate Er12$989$82
Hydrocodone-Acetaminophen22$799$36
Oxycodone29$750$26
Ondansetron56$749$13
Dexamethasone23$559$24
Bicalutamide20$546$27
Prochlorperazine Maleate63$450$7
Letrozole13$430$33
Venlafaxine21$332$16
Gabapentin23$312$14
Lorazepam54$216$4
Lisinopril14$123$9
Pantoprazole18$100$6
Alendronate14$80$6
Amlodipine Besylate16$49$3

2015: 24 drugs

Part D drugs prescribed in 2015
Ibrance14$140,561$10,040
Tarceva20$135,172$6,759
Exemestane53$17,314$327
Xarelto13$4,884$376
Oxycontin11$4,133$376
Spiriva11$3,437$312
Anastrozole204$3,195$16
Raloxifene12$2,562$214
Tamoxifen Citrate86$2,456$29
Ondansetron49$1,983$40
Bicalutamide20$808$40
Oxycodone20$655$33
Prochlorperazine Maleate34$391$11
Potassium Chloride13$374$29
Megestrol Acetate14$359$26
Venlafaxine16$339$21
Hydrocodone-Acetaminophen12$328$27
Letrozole13$282$22
Warfarin22$237$11
Gabapentin14$233$17
Lorazepam30$172$6
Levofloxacin15$149$10
Dexamethasone18$131$7
Pantoprazole18$108$6

2014: 23 drugs

Part D drugs prescribed in 2014
Nexavar11$122,073$11,098
Tarceva17$106,441$6,261
Enoxaparin17$21,724$1,278
Exemestane25$11,878$475
Xarelto14$8,503$607
Anastrozole156$3,855$25
Tamoxifen Citrate88$2,763$31
Ondansetron27$1,230$46
Hydrocodone-Acetaminophen30$1,137$38
Gabapentin14$906$65
Megestrol Acetate17$898$53
Potassium Chloride15$772$51
Prochlorperazine Maleate29$418$14
Oxycodone19$359$19
Lactulose23$245$11
Pantoprazole15$178$12
Levofloxacin12$168$14
Lorazepam23$113$5
Warfarin17$112$7
Spironolactone11$94$9
Amlodipine Besylate12$75$6
Chlorhexidine Gluconate12$59$5
Clonidine13$54$4

2013: 27 drugs

Part D drugs prescribed in 2013
Gleevec13$88,743$6,826
Neupogen23$70,780$3,077
Tarceva11$58,519$5,320
Enoxaparin29$35,404$1,221
Exemestane31$13,028$420
Cymbalta18$7,598$422
Fondaparinux11$6,119$556
Anastrozole138$5,206$38
Lyrica15$4,606$307
Oxycontin19$3,798$200
Tamoxifen Citrate84$2,124$25
Gabapentin29$1,819$63
Ondansetron28$1,740$62
Potassium Chloride36$973$27
Venlafaxine16$836$52
Oxycodone29$646$22
Hydrocodone-Acetaminophen30$636$21
Pantoprazole30$545$18
Prochlorperazine Maleate29$360$12
Nystatin12$350$29
Letrozole15$276$18
Lorazepam47$270$6
Warfarin15$176$12
Amlodipine Besylate21$168$8
Carisoprodol12$136$11
Clonidine14$93$7
Zolpidem11$69$6

Money from drug and device companies

$6,587 in 2025

Industry payments by year
20252036$5,472$6,587
20241023$3,330$4,263
20231326$11,628$13,794
20221327$9,866$12,335
202126105$60,714$68,625
20202454$23,278$24,081
20192884$2,500$5,783

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Bayer Healthcare PharmaceuticalsNone$2,272
2 payments
  • Consulting · 2025-05-31 · $2,142
  • Meals · 2025-05-31 · $130
AstraZeneca Pharmaceuticals LPDatroway$1,248
3 payments
  • Consulting for Datroway · 2025-11-12 · $670
  • Education · 2025-04-21 · $23
  • Consulting for Datroway · 2025-04-11 · $555
Gilead SciencesTrodelvy$1,183
3 payments
  • Consulting for Trodelvy · 2025-12-18 · $580
  • Meals for Trodelvy · 2025-05-27 · $23
  • Consulting for Trodelvy · 2025-05-15 · $580
PfizerBosulif$974
2 payments
  • Consulting · 2025-11-12 · $945
  • Meals for Bosulif · 2025-01-13 · $29
Stemline TherapeuticsOrserdu$218
2 payments
  • Meals for Orserdu · 2025-08-22 · $68
  • Meals for Orserdu · 2025-08-20 · $150
CelgeneReblozyl$201
7 payments
  • Meals for Reblozyl · 2025-10-24 · $28
  • Meals for Opdivo · 2025-09-15 · $33
  • Meals for Reblozyl · 2025-08-19 · $31
  • Meals for Reblozyl · 2025-06-25 · $30
  • Meals for Reblozyl · 2025-03-11 · $26
  • Meals for Opdivo · 2025-02-04 · $34
  • Meals for Reblozyl · 2025-01-09 · $18
See all 36 published payments
Every published payment
Gilead SciencesConsulting · 2025-12-18Trodelvy$580
AstraZeneca Pharmaceuticals LPConsulting · 2025-11-12Datroway$670
PfizerConsulting · 2025-11-12None$945
Puma BiotechnologyMeals · 2025-11-11Nerlynx$22
Takeda Pharmaceuticals U.S.A.Meals · 2025-11-06Iclusig$25
CelgeneMeals · 2025-10-24Reblozyl$28
GlaxoSmithKlineMeals · 2025-09-16Ojjaara$29
CelgeneMeals · 2025-09-15Opdivo$33
Kite PharmaMeals · 2025-08-27Yescarta$22
Stemline TherapeuticsMeals · 2025-08-22Orserdu$68
Stemline TherapeuticsMeals · 2025-08-20Orserdu$150
CelgeneMeals · 2025-08-19Reblozyl$31
Merck Sharp & DohmeMeals · 2025-08-05Keytruda$28
CelgeneMeals · 2025-06-25Reblozyl$30
Array BiopharmaMeals · 2025-06-13Lorbrena$33
GlaxoSmithKlineMeals · 2025-06-04Ojjaara$20
Bayer Healthcare PharmaceuticalsConsulting · 2025-05-31None$2,142
Bayer Healthcare PharmaceuticalsMeals · 2025-05-31None$130
Genentech USAMeals · 2025-05-28Venclexta$29
Gilead SciencesMeals · 2025-05-27Trodelvy$23
Gilead SciencesConsulting · 2025-05-15Trodelvy$580
Kite PharmaMeals · 2025-05-12Yescarta$16
AstraZeneca Pharmaceuticals LPEducation · 2025-04-21None$23
Janssen BiotechEducation · 2025-04-16Darzalex$99
Tactile Systems TechnologyMeals · 2025-04-15Flexitouch Plus$22
SpringWorks TherapeuticsMeals · 2025-04-15Ogsiveo$20
AstraZeneca Pharmaceuticals LPConsulting · 2025-04-11Datroway$555
Recordati Rare Diseases Inc.Meals · 2025-03-24Enjaymo$28
CelgeneMeals · 2025-03-11Reblozyl$26
Rigel PharmaceuticalsMeals · 2025-02-06Tavalisse$29
CelgeneMeals · 2025-02-04Opdivo$34
Rigel PharmaceuticalsMeals · 2025-01-28Tavalisse$27
AbbvieMeals · 2025-01-22Epkinly$22
PfizerMeals · 2025-01-13Bosulif$29
CelgeneMeals · 2025-01-09Reblozyl$18
Adc Therapeutics AmericaMeals · 2025-01-06Zynlonta$19
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $4,263

Payments by company in 2024
AstraZeneca Pharmaceuticals LPTruqap$3,559
8 payments
  • Consulting · 2024-11-19 · $1,110
  • Consulting · 2024-11-14 · $555
  • Meals · 2024-11-09 · $135
  • Meals · 2024-09-17 · $31
  • Meals · 2024-07-16 · $30
  • Consulting for Truqap · 2024-05-13 · $1,665
  • Meals · 2024-02-02 · $20
  • Meals · 2024-02-02 · $14
Stemline TherapeuticsOrserdu$177
1 payment
  • Meals for Orserdu · 2024-08-23 · $177
Gilead SciencesTrodelvy$131
1 payment
  • Meals for Trodelvy · 2024-08-23 · $131
Puma BiotechnologyNone$109
2 payments
  • Meals · 2024-08-16 · $80
  • Meals · 2024-06-18 · $28
CelgeneReblozyl$71
3 payments
  • Meals for Reblozyl · 2024-10-30 · $14
  • Meals for Reblozyl · 2024-06-11 · $31
  • Meals · 2024-05-23 · $26
AbbvieImbruvica$69
3 payments
  • Meals for Imbruvica · 2024-10-14 · $20
  • Meals for Imbruvica · 2024-09-17 · $25
  • Meals for Epkinly · 2024-05-06 · $23
Array BiopharmaXalkori$56
2 payments
  • Meals for Xalkori · 2024-12-18 · $26
  • Meals for Xalkori · 2024-08-27 · $29
GlaxoSmithKlineJemperli$32
1 payment
  • Meals for Jemperli · 2024-04-19 · $32
Kite PharmaYescarta$32
1 payment
  • Meals for Yescarta · 2024-11-22 · $32
EisaiLenvima$29
1 payment
  • Meals for Lenvima · 2024-11-12 · $29

2023: $13,794

Payments by company in 2023
SeagenTukysa$9,615
7 payments
  • Consulting for Tukysa · 2023-05-26 · $8,125
  • Travel for Tukysa · 2023-05-12 · $331
  • Meals for Tukysa · 2023-05-12 · $25
  • Meals for Tukysa · 2023-05-12 · $59
  • Travel for Tukysa · 2023-05-12 · $144
  • Travel for Tukysa · 2023-05-11 · $610
  • Travel for Tukysa · 2023-05-11 · $320
Novartis PharmaceuticalsKisqali$1,838
1 payment
  • Consulting for Kisqali · 2023-12-07 · $1,838
AstraZeneca Pharmaceuticals LPCalquence$1,733
3 payments
  • Meals · 2023-12-07 · $43
  • Consulting · 2023-08-23 · $1,665
  • Meals for Calquence · 2023-05-01 · $25
Gilead SciencesTrodelvy$118
1 payment
  • Meals for Trodelvy · 2023-12-09 · $118
Puma BiotechnologyNerlynx$96
1 payment
  • Meals for Nerlynx · 2023-07-12 · $96
ADC Therapeutics AmericaNone$86
1 payment
  • Meals · 2023-10-04 · $86
Stemline TherapeuticsOrserdu$80
2 payments
  • Meals for Orserdu · 2023-12-03 · $58
  • Meals for Orserdu · 2023-02-28 · $23
Daiichi SankyoInjectafer$67
3 payments
  • Meals for Enhertu · 2023-11-13 · $21
  • Meals for Injectafer · 2023-05-03 · $23
  • Meals for Injectafer · 2023-01-31 · $23
CelgeneReblozyl$54
2 payments
  • Meals · 2023-03-29 · $26
  • Meals for Reblozyl · 2023-03-10 · $27
PfizerXtandi$35
2 payments
  • Meals for Xtandi · 2023-07-12 · $17
  • Meals for Xtandi · 2023-04-18 · $18
CTI BioPharmaVonjo$28
1 payment
  • Meals for Vonjo · 2023-08-08 · $28
Janssen BiotechImbruvica$25
1 payment
  • Meals for Imbruvica · 2023-04-17 · $25
Merck Sharp & DohmeKeytruda$19
1 payment
  • Meals for Keytruda · 2023-06-15 · $19

2022: $12,335

Payments by company in 2022
Lilly USAVerzenio$6,250
1 payment
  • Paid to speak or teach for Verzenio · 2022-04-19 · $6,250
Gilead SciencesTrodelvy$5,489
12 payments
  • Consulting for Trodelvy · 2022-12-08 · $3,416
  • Travel for Trodelvy · 2022-10-29 · $218
  • Travel for Trodelvy · 2022-10-29 · $241
  • Travel for Trodelvy · 2022-10-29 · $317
  • Travel for Trodelvy · 2022-10-28 · $252
  • Travel for Trodelvy · 2022-10-28 · $315
  • Travel for Trodelvy · 2022-10-28 · $331
  • Travel for Trodelvy · 2022-10-28 · $363
  • Meals for Trodelvy · 2022-10-19 · $18
  • Meals for Trodelvy · 2022-10-18 · $1
  • Meals for Trodelvy · 2022-08-30 · $1
  • Meals for Trodelvy · 2022-08-30 · $17
Novocure GmbHNone$200
1 payment
  • Honoraria · 2022-01-19 · $200
Puma BiotechnologyNerlynx$120
1 payment
  • Meals for Nerlynx · 2022-09-12 · $120
AmgenNplate$49
2 payments
  • Meals for Lumakras · 2022-11-01 · $19
  • Meals for Nplate · 2022-08-16 · $31
Pharmacyclics LLC an AbbVieImbruvica$47
2 payments
  • Meals for Imbruvica · 2022-06-24 · $30
  • Meals for Imbruvica · 2022-05-11 · $17
Janssen BiotechImbruvica$41
2 payments
  • Meals for Imbruvica · 2022-12-19 · $24
  • Meals for Rybrevant · 2022-09-20 · $17
SeagenTivdak$26
1 payment
  • Meals for Tivdak · 2022-09-01 · $26
AstraZeneca Pharmaceuticals LPLynparza$24
1 payment
  • Meals for Lynparza · 2022-10-13 · $24
Novartis PharmaceuticalsNone$24
1 payment
  • Meals · 2022-06-27 · $24
Clovis OncologyNone$22
1 payment
  • Meals · 2022-06-02 · $22
GlaxoSmithKlineZejula$22
1 payment
  • Meals for Zejula · 2022-05-11 · $22
Myriad Genetic LaboratoriesPrecisetumor$20
1 payment
  • Meals for Precisetumor · 2022-10-06 · $20

2021: $68,625

Payments by company in 2021
SeagenTukysa$28,300
20 payments
  • Meals for Adcetris · 2021-12-02 · $14
  • Meals for Adcetris · 2021-12-02 · $24
  • Paid to speak or teach for Tukysa · 2021-11-09 · $1,235
  • Meals for Tukysa · 2021-10-28 · $120
  • Travel for Tukysa · 2021-10-28 · $165
  • Paid to speak or teach for Tukysa · 2021-10-28 · $7,480
  • Travel for Tukysa · 2021-10-28 · $584
  • Meals for Tukysa · 2021-10-25 · $76
  • Travel for Tukysa · 2021-10-25 · $237
  • Paid to speak or teach for Tukysa · 2021-10-25 · $8,140
  • Travel for Tukysa · 2021-10-25 · $971
  • Travel for Tukysa · 2021-10-25 · $403
  • Meals for Padcev · 2021-09-24 · $16
  • Meals for Tukysa · 2021-08-26 · $93
  • Paid to speak or teach for Tukysa · 2021-08-26 · $3,520
  • Travel for Tukysa · 2021-08-26 · $333
  • Meals for Tukysa · 2021-06-18 · $26
  • Meals for Tukysa · 2021-05-20 · $107
  • Paid to speak or teach for Tukysa · 2021-05-20 · $3,520
  • Paid to speak or teach for Tukysa · 2021-03-10 · $1,235
Puma BiotechnologyNerlynx$14,341
13 payments
  • Consulting for Nerlynx · 2021-11-15 · $1,650
  • Paid to speak or teach for Nerlynx · 2021-10-08 · $2,500
  • Meals for Nerlynx · 2021-10-07 · $123
  • Paid to speak or teach for Nerlynx · 2021-08-17 · $2,500
  • Travel for Nerlynx · 2021-08-13 · $385
  • Meals for Nerlynx · 2021-08-11 · $124
  • Travel for Nerlynx · 2021-08-05 · $25
  • Paid to speak or teach for Nerlynx · 2021-07-19 · $2,500
  • Meals for Nerlynx · 2021-07-08 · $109
  • Paid to speak or teach for Nerlynx · 2021-06-16 · $2,500
  • Meals for Nerlynx · 2021-06-10 · $125
  • Consulting for Nerlynx · 2021-03-30 · $450
  • Paid to speak or teach for Nerlynx · 2021-03-26 · $1,350
Daiichi SankyoEnhertu$11,338
11 payments
  • Paid to speak or teach for Enhertu · 2021-12-20 · $1,100
  • Consulting for Enhertu · 2021-11-03 · $416
  • Paid to speak or teach for Enhertu · 2021-10-06 · $2,200
  • Meals for Enhertu · 2021-09-30 · $113
  • Travel for Enhertu · 2021-09-30 · $386
  • Paid to speak or teach for Enhertu · 2021-08-12 · $3,350
  • Meals for Enhertu · 2021-08-05 · $83
  • Travel for Enhertu · 2021-08-05 · $536
  • Paid to speak or teach for Enhertu · 2021-06-30 · $2,200
  • Meals for Enhertu · 2021-06-24 · $120
  • Paid to speak or teach for Enhertu · 2021-06-16 · $833
AstraZeneca Pharmaceuticals LPLynparza$8,915
11 payments
  • Paid to speak or teach · 2021-11-21 · $2,200
  • Paid to speak or teach · 2021-11-07 · $2,200
  • Meals · 2021-11-05 · $24
  • Travel · 2021-11-04 · $633
  • Meals for Lynparza · 2021-11-04 · $0
  • Meals · 2021-11-04 · $125
  • Travel · 2021-09-01 · $773
  • Meals · 2021-09-01 · $104
  • Paid to speak or teach · 2021-07-11 · $2,200
  • Meals · 2021-06-16 · $100
  • Consulting · 2021-03-28 · $555
Karyopharm TherapeuticsXpovio$2,288
3 payments
  • Meals for Xpovio · 2021-07-02 · $30
  • Consulting for Xpovio · 2021-06-22 · $2,250
  • Meals for Xpovio · 2021-05-06 · $8
GenzymeNone$2,280
1 payment
  • Consulting · 2021-09-15 · $2,280
Athenex Pharmaceutical DivisionNone$350
2 payments
  • Honoraria · 2021-01-19 · $175
  • Honoraria · 2021-01-14 · $175
Pharmacyclics LLC an AbbVieImbruvica$170
10 payments
  • Meals for Imbruvica · 2021-12-08 · $15
  • Meals for Imbruvica · 2021-12-02 · $1
  • Meals for Imbruvica · 2021-11-30 · $11
  • Meals for Imbruvica · 2021-11-24 · $12
  • Meals for Imbruvica · 2021-11-18 · $13
  • Meals for Imbruvica · 2021-10-22 · $14
  • Meals for Imbruvica · 2021-10-11 · $22
  • Meals for Imbruvica · 2021-07-26 · $30
  • Meals for Imbruvica · 2021-07-21 · $29
  • Meals for Imbruvica · 2021-05-12 · $23
PfizerInlyta$140
9 payments
  • Meals for Ibrance · 2021-12-03 · $20
  • Education for Inlyta · 2021-12-03 · $26
  • Education for Inlyta · 2021-11-16 · $8
  • Education for Inlyta · 2021-11-02 · $8
  • Education for Ibrance · 2021-10-04 · $13
  • Education for Ibrance · 2021-08-23 · $32
  • Education for Inlyta · 2021-04-28 · $13
  • Education for Inlyta · 2021-04-28 · $8
  • Education for Inlyta · 2021-03-24 · $13
Janssen BiotechErleada$67
3 payments
  • Meals for Erleada · 2021-11-08 · $19
  • Meals for Darzalex · 2021-10-08 · $24
  • Meals for Erleada · 2021-05-14 · $24
Lilly USACyramza$59
2 payments
  • Meals for Cyramza · 2021-09-18 · $28
  • Meals for Cyramza · 2021-05-29 · $30
Pharmacosmos TherapeuticsMonoferric$41
3 payments
  • Education for Monoferric · 2021-12-17 · $13
  • Education for Monoferric · 2021-12-17 · $14
  • Education for Monoferric · 2021-12-17 · $14
Coherus BiosciencesUdenyca$39
1 payment
  • Meals for Udenyca · 2021-11-18 · $39
IncyteJakafi$35
2 payments
  • Meals for Jakafi · 2021-09-23 · $19
  • Meals for Jakafi · 2021-09-10 · $16
CelgenePomalyst$32
2 payments
  • Meals for Pomalyst · 2021-10-22 · $17
  • Meals for Abecma · 2021-05-21 · $14
Novartis PharmaceuticalsKisqali$31
2 payments
  • Meals for Tabrecta · 2021-11-03 · $13
  • Meals for Kisqali · 2021-09-14 · $18
AmgenLumakras$26
1 payment
  • Meals for Lumakras · 2021-10-01 · $26
AMAG PharmaceuticalsFeraheme$24
1 payment
  • Meals for Feraheme · 2021-08-20 · $24
ExelixisCabometyx$22
1 payment
  • Meals for Cabometyx · 2021-07-10 · $22
AbbVieCreon$22
1 payment
  • Meals for Creon · 2021-11-01 · $22
Merck Sharp & DohmeKeytruda$21
1 payment
  • Meals for Keytruda · 2021-06-11 · $21
EisaiLenvima$21
1 payment
  • Meals for Lenvima · 2021-07-16 · $21
BeiGene USABrukinsa$19
1 payment
  • Meals for Brukinsa · 2021-08-06 · $19
E.R. Squibb & Sons L.L.C.Opdivo$18
1 payment
  • Meals for Opdivo · 2021-10-15 · $18
Astellas Pharma USXtandi$17
1 payment
  • Meals for Xtandi · 2021-07-23 · $17
Gilead SciencesNone$12
1 payment
  • Education · 2021-06-01 · $12

2020: $24,081

Payments by company in 2020
Daiichi SankyoEnhertu$8,139
9 payments
  • Paid to speak or teach for Enhertu · 2020-11-19 · $1,100
  • Meals for Enhertu · 2020-10-22 · $22
  • Meals for Enhertu · 2020-10-21 · $1
  • Paid to speak or teach for Enhertu · 2020-08-20 · $1,100
  • Meals for Enhertu · 2020-05-29 · $28
  • Paid to speak or teach for Enhertu · 2020-04-07 · $833
  • Meals for Enhertu · 2020-02-11 · $119
  • Education for Enhertu · 2020-01-31 · $2
  • Consulting for Enhertu · 2020-01-21 · $4,935
Puma BiotechnologyNerlynx$5,830
9 payments
  • Paid to speak or teach for Nerlynx · 2020-12-07 · $1,100
  • Paid to speak or teach for Nerlynx · 2020-10-26 · $1,100
  • Consulting for Nerlynx · 2020-10-23 · $500
  • Consulting for Nerlynx · 2020-09-28 · $450
  • Paid to speak or teach for Nerlynx · 2020-07-13 · $1,100
  • Paid to speak or teach for Nerlynx · 2020-06-24 · $1,100
  • Education for Nerlynx · 2020-06-08 · $6
  • Meals for Nerlynx · 2020-06-05 · $23
  • Consulting for Nerlynx · 2020-05-19 · $450
AstraZeneca Pharmaceuticals LPNone$4,465
2 payments
  • Consulting · 2020-10-07 · $1,665
  • Consulting · 2020-06-24 · $2,800
SeagenTukysa$2,374
4 payments
  • Consulting for Tukysa · 2020-09-24 · $1,375
  • Education for Tukysa · 2020-09-01 · $56
  • Meals for Tukysa · 2020-06-23 · $23
  • Paid to speak or teach for Tukysa · 2020-04-30 · $920
ImmunomedicsTrodelvy$1,750
1 payment
  • Paid to speak or teach for Trodelvy · 2020-11-23 · $1,750
Rigel PharmaceuticalsTavalisse$1,012
2 payments
  • Meals for Tavalisse · 2020-07-24 · $12
  • Paid to speak or teach for Tavalisse · 2020-05-19 · $1,000
Janssen BiotechImbruvica$68
5 payments
  • Meals for Imbruvica · 2020-10-09 · $11
  • Meals for Erleada · 2020-07-31 · $20
  • Meals for Imbruvica · 2020-05-18 · $12
  • Meals for Imbruvica · 2020-02-08 · $12
  • Meals for Imbruvica · 2020-01-18 · $13
ExelixisCabometyx$48
2 payments
  • Meals for Cabometyx · 2020-06-19 · $18
  • Meals for Cabometyx · 2020-04-22 · $31
Alexion PharmaceuticalsUltomiris$41
2 payments
  • Meals for Ultomiris · 2020-10-26 · $20
  • Meals for Ultomiris · 2020-05-21 · $22
E.R. Squibb & Sons L.L.C.Opdivo$39
2 payments
  • Meals · 2020-11-20 · $17
  • Meals for Opdivo · 2020-08-10 · $22
PfizerXalkori$38
3 payments
  • Education for Inlyta · 2020-08-19 · $13
  • Education for Lorbrena · 2020-02-26 · $11
  • Education for Xalkori · 2020-02-26 · $14
Astellas Pharma USPadcev$25
1 payment
  • Meals for Padcev · 2020-08-21 · $25
Lilly USACyramza$24
1 payment
  • Meals for Cyramza · 2020-09-25 · $24
Jazz PharmaceuticalsVyxeos$24
1 payment
  • Meals for Vyxeos · 2020-01-25 · $24
AbbVieVenclexta$24
1 payment
  • Meals for Venclexta · 2020-03-06 · $24
Takeda Pharmaceuticals U.S.A.Alunbrig$22
1 payment
  • Meals for Alunbrig · 2020-07-28 · $22
Array BiopharmaBraftovi$22
1 payment
  • Meals for Braftovi · 2020-11-12 · $22
Blueprint MedicinesAyvakit$22
1 payment
  • Meals for Ayvakit · 2020-06-26 · $22
EisaiLenvima$21
1 payment
  • Meals for Lenvima · 2020-10-02 · $21
Dova PharmaceuticalsDoptelet$21
1 payment
  • Meals for Doptelet · 2020-02-28 · $21
AmgenNeulasta$20
1 payment
  • Meals for Neulasta · 2020-11-19 · $20
Mylan InstitutionalOgivri$20
1 payment
  • Meals for Ogivri · 2020-09-11 · $20
Genentech USAVenclexta$19
1 payment
  • Meals for Venclexta · 2020-08-28 · $19
Aurobindo Pharma USAFolotyn$15
1 payment
  • Meals for Folotyn · 2020-09-18 · $15

2019: $5,783

Payments by company in 2019
Seattle GeneticsAdcetris$1,749
6 payments
  • Meals · 2019-11-22 · $24
  • Meals for Adcetris · 2019-11-22 · $20
  • Meals · 2019-10-11 · $22
  • Meals for Adcetris · 2019-03-15 · $125
  • Paid to speak or teach for Adcetris · 2019-03-15 · $1,500
  • Travel for Adcetris · 2019-03-15 · $58
Puma BiotechnologyNerlynx$1,232
6 payments
  • Meals for Nerlynx · 2019-11-14 · $21
  • Travel for Nerlynx · 2019-06-14 · $15
  • Travel for Nerlynx · 2019-06-14 · $47
  • Meals for Nerlynx · 2019-05-14 · $125
  • Consulting for Nerlynx · 2019-05-14 · $1,000
  • Meals for Nerlynx · 2019-01-11 · $24
Daiichi SankyoEnhertu$766
5 payments
  • Meals for Enhertu · 2019-07-28 · $62
  • Meals for Enhertu · 2019-07-28 · $90
  • Meals for Enhertu · 2019-07-28 · $30
  • Travel for Enhertu · 2019-07-27 · $416
  • Travel for Enhertu · 2019-07-27 · $168
Novartis PharmaceuticalsKisqali$283
5 payments
  • Meals for Tasigna · 2019-12-09 · $13
  • Meals for Kisqali · 2019-10-10 · $115
  • Meals for Tasigna · 2019-08-16 · $25
  • Meals for Mekinist · 2019-07-01 · $17
  • Meals · 2019-04-11 · $114
Sirtex MedicalSir-Spheres Microspheres$257
1 payment
  • Meals for Sir-Spheres Microspheres · 2019-08-28 · $257
Janssen BiotechErleada$184
9 payments
  • Meals for Imbruvica · 2019-11-26 · $15
  • Meals for Imbruvica · 2019-10-25 · $9
  • Meals for Darzalex · 2019-08-23 · $16
  • Meals for Erleada · 2019-07-09 · $108
  • Meals for Erleada · 2019-06-20 · $13
  • Meals for Erleada · 2019-04-30 · $2
  • Meals for Darzalex · 2019-02-01 · $6
  • Meals for Darzalex · 2019-02-01 · $15
  • Meals for Erleada · 2019-02-01 · $1
ExelixisCabometyx$158
9 payments
  • Meals for Cabometyx · 2019-09-18 · $20
  • Meals for Cabometyx · 2019-09-16 · $2
  • Meals for Cabometyx · 2019-09-16 · $1
  • Meals for Cabometyx · 2019-09-09 · $67
  • Meals for Cabometyx · 2019-08-10 · $12
  • Meals for Cabometyx · 2019-08-10 · $11
  • Meals for Cabometyx · 2019-05-28 · $23
  • Meals for Cabometyx · 2019-05-28 · $2
  • Meals for Cabometyx · 2019-03-30 · $21
Lilly USAVerzenio$156
3 payments
  • Meals for Alimta · 2019-08-31 · $23
  • Meals for Erbitux · 2019-06-06 · $23
  • Meals for Verzenio · 2019-03-16 · $111
AstraZeneca Pharmaceuticals LPTagrisso$142
3 payments
  • Meals for Lynparza · 2019-04-27 · $16
  • Meals for Imfinzi · 2019-04-25 · $4
  • Meals for Tagrisso · 2019-03-21 · $122
AbbVieVenclexta$136
1 payment
  • Meals for Venclexta · 2019-05-29 · $136
CelgeneInrebic$122
3 payments
  • Meals for Inrebic · 2019-12-12 · $78
  • Meals for Revlimid · 2019-09-20 · $23
  • Meals for Abraxane · 2019-03-07 · $21
AmgenKyprolis$77
4 payments
  • Meals for Kyprolis · 2019-10-14 · $24
  • Meals for Mvasi · 2019-08-19 · $20
  • Meals for Kanjinti · 2019-07-26 · $22
  • Education · 2019-07-26 · $11
Bayer HealthCare PharmaceuticalsVitrakvi$74
3 payments
  • Meals for Nubeqa · 2019-09-13 · $25
  • Meals for Vitrakvi · 2019-07-19 · $24
  • Meals for Vitrakvi · 2019-02-04 · $25
GenzymeElitek$47
2 payments
  • Meals for Jevtana · 2019-11-15 · $22
  • Meals for Elitek · 2019-05-24 · $25
EisaiLenvima$47
2 payments
  • Meals for Lenvima · 2019-11-18 · $25
  • Meals for Halaven · 2019-05-13 · $22
Pharmacyclics LLC An AbbVieImbruvica$45
2 payments
  • Meals for Imbruvica · 2019-09-09 · $22
  • Meals for Imbruvica · 2019-04-05 · $22
Rigel PharmaceuticalsTavalisse$42
2 payments
  • Meals for Tavalisse · 2019-07-29 · $22
  • Meals for Tavalisse · 2019-04-26 · $20
PfizerIbrance$42
3 payments
  • Education for Bavencio · 2019-10-18 · $15
  • Education for Lorbrena · 2019-10-18 · $11
  • Meals for Ibrance · 2019-06-10 · $16
Merck Sharp & DohmeKeytruda$35
2 payments
  • Meals · 2019-07-05 · $20
  • Meals for Keytruda · 2019-01-28 · $15
IncyteJakafi$34
2 payments
  • Meals for Jakafi · 2019-10-22 · $18
  • Meals for Jakafi · 2019-04-13 · $16
Servier PharmaceuticalsOncaspar$24
1 payment
  • Meals for Oncaspar · 2019-05-10 · $24
Alexion PharmaceuticalsUltomiris$24
1 payment
  • Meals for Ultomiris · 2019-12-14 · $24
Boehringer Ingelheim PharmaceuticalsGilotrif$22
1 payment
  • Meals for Gilotrif · 2019-03-01 · $22
Genentech USAGazyva$21
1 payment
  • Meals for Gazyva · 2019-01-07 · $21
Clovis OncologyRubraca$19
2 payments
  • Meals for Rubraca · 2019-05-31 · $18
  • Meals for Rubraca · 2019-05-31 · $1
VerastemCopiktra$17
1 payment
  • Meals for Copiktra · 2019-06-07 · $17
Spectrum PharmaceuticalsFolotyn$16
1 payment
  • Meals for Folotyn · 2019-02-25 · $16
Astellas Pharma USPadcev$15
2 payments
  • Meals for Padcev · 2019-12-31 · $15
  • Meals for Padcev · 2019-12-30 · $0

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2021Their institution$2,821
Novartis Pharmaceuticals Corporation · An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Hr Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy · 2019Their institution$1,244
Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2023Their institution$435
Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2022Their institution$150

Professional record

NPI
1174777643
Licence
CA A74043California A74043: Current · expires 2026-11-30
Trained
Jefferson Medical College of Thomas Jefferson University, 1999
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X); Federal specialty code 174400000X (174400000X); Federal specialty code 207RH0000X (207RH0000X)
Mailing address
300 Pasteur Dr, Palo Alto, CA, 94304
NPI first listed
2008-11-11
NPI last updated
2024-04-28
NPI record certified
2024-04-28

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 2001 Dwight Way, Berkeley, CA, 94704